Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Authoritative Statements For Health Claims Up To Agency Heads - Yetley

This article was originally published in The Tan Sheet

Executive Summary

Appropriate authoritative statements for dietary supplement health claims should be determined by the director of the agency from which the claim originates, Center for Food Safety & Applied Nutrition Office of Special Nutritionals Director Elizabeth Yetley, PhD, asserted at a Nonprescription Drug Manufacturers Association meeting on dietary supplements in Washington, D.C. Jan. 15.

You may also be interested in...



FDA 100-Day Health Claim Review Provided In House Bill

FDA would be required to authorize general health claims and "claims based on government statements" within 100 days of receipt under the "Consumer Freedom Protection Act." Currently, the agency has 540 days to review a proposed health claim.

FDA 100-Day Health Claim Review Provided In House Bill

FDA would be required to authorize general health claims and "claims based on government statements" within 100 days of receipt under the "Consumer Freedom Protection Act." Currently, the agency has 540 days to review a proposed health claim.

FDA 100-Day Health Claim Review Provided In House Bill

FDA would be required to authorize general health claims and "claims based on government statements" within 100 days of receipt under the "Consumer Freedom Protection Act." Currently, the agency has 540 days to review a proposed health claim.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel